RESUMEN
Body weight, body mass index (BMI), Nutrition Risk Screening 2002 (NRS2002), and prognostic nutritional index (PNI) are among vital nutrition status indices employed during cancer treatment. These have also been associated with levels of blood chemistry panels (BCPs), which are touted as significant indicators of disease prognosis. However, it remains unclear which nutrition status index better predicts future trends in specific BCPs. Using the records of 407 cancer patients, we retrospectively examined the potential of nutritional status indices at baseline for predicting changes in specific BCPs over a 6-week period. Generally, both serum biochemical parameters and nutrition status indices fluctuated over the study period among study participants. PNI was often linearly associated with blood cell counts (white blood cells [WBCs] and hemoglobin) compared with anthropometric-based nutrition status indices. Increase in body weight was protective against having abnormal lymphocyte levels at 6 weeks (odds ratio [OR]: 0.960-0.974; CI: 0.935-0.997; P < 0.05), while increase in baseline PNI was associated with 0.865-0.941 and 0.675-0.915 odds of having future abnormal WBC and lymphocyte levels, respectively. Increases in PNI were also protective against having future abnormal albumin levels (OR: 0.734-0.886) and 8.5-12.5% decreases in the odds of having an abnormal C-reactive protein level in subsequent visits. Changes in NRS2002 tended to be associated with the odds of having future abnormal blood glucose levels. In conclusion, the serum biochemistry-derived nutrition status index, PNI, is a more consistent measure as an early indicator to track the trends of future changes in the BCPs of cancer patients. This implies that PNI could be targeted as an early-warning measure with relevant preventive interventions for patients at risk of malnutrition.
Asunto(s)
Índice de Masa Corporal , Neoplasias , Evaluación Nutricional , Estado Nutricional , Humanos , Masculino , Femenino , Neoplasias/sangre , Estudios Retrospectivos , Persona de Mediana Edad , Pronóstico , Anciano , Adulto , Peso Corporal , Antropometría/métodos , Hemoglobinas/análisis , Recuento de LeucocitosRESUMEN
SCOPE: Grifola frondosa has been shown to induce immune modulatory, modulate autophagy, and apoptosis in cancer cells. However, little is known about its potential for managing tumor progression as an adjunct to nutrient restriction. METHODS AND RESULTS: Water extract produces a G. frondosa polysaccharide-protein complex (G. frondosa PPC) of average molecular weight of 46.48 kDa, with glucose (54.8%) as the main constituent. Under serum-restricted conditions, G. frondosa PPC can significantly inhibit MC38 colorectal tumor cell migration in vitro. Under alternate-day fasting condition, G. frondosa PPC can only significantly inhibit the growth of subcutaneous (s.c.) tumor, but is feeble in halting its spread in the intraperitoneal (i.p.) cavity in tumor-bearing mice. Histopathological examination and Raman imaging show a significant increase in lipid content in the tumor microenvironment (TME) tissue of the s.c. tumor-bearing mice. G. frondosa PPC significantly increases C17:0 and C24:0 saturated fatty acids and significantly decreases C16:1 and C18:1 monounsaturated fatty acids in the TME of s.c. tumor-bearing mice compared with the i.p. cavity model. CONCLUSION: G. frondosa PPC significantly inhibits tumor growth in s.c. tumor-bearing mice under intermittent fasting conditions by altering the fatty acid composition of the TME.
Asunto(s)
Neoplasias del Colon , Ayuno , Grifola , Animales , Grifola/química , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/patología , Línea Celular Tumoral , Ratones , Polisacáridos/farmacología , Microambiente Tumoral/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Ácidos Grasos/farmacología , Masculino , Ratones Endogámicos C57BL , Agua/químicaRESUMEN
In spite of recent advances in the field of undernutrition, current dietary therapy relying on the supply of high protein high calorie formulas is still plagued with transient recovery of impaired organs resulting in significant relapse of cases. This is partly attributed to the inadequacy of current research models in recapitulating clinical undernutrition for mechanistic exploration. Using 1636 Macaca fascicularis monkeys, a human-relevant criterion for determining undernutrition weight-for-age z-score (WAZ), with a cutoff point of ≤ -1.83 is established as the benchmark for identifying undernourished nonhuman primates (U-NHPs). In U-NHPs, pathological anomalies in multi-organs are revealed. In particular, severe dysregulation of hepatic lipid metabolism characterized by impaired fatty acid oxidation due to mitochondria dysfunction, but unlikely peroxisome disorder, is identified as the anchor metabolic aberration in U-NHPs. Mitochondria dysfunction is typified by reduced mito-number, accumulated long-chain fatty acids, and disruption of OXPHOS complexes. Soy peptide-treated U-NHPs increase in WAZ scores, in addition to attenuated mitochondria dysfunction and restored OXPHOS complex levels. Herein, innovative criteria for identifying U-NHPs are developed, and unknown molecular mechanisms of undernutrition are revealed hitherto, and it is further proved that soypeptide supplementation reprogramed mitochondrial function to re-establish lipid metabolism balance and mitigated undernutrition.
Asunto(s)
Modelos Animales de Enfermedad , Hígado , Macaca fascicularis , Desnutrición , Animales , Desnutrición/metabolismo , Hígado/metabolismo , Hígado/efectos de los fármacos , Suplementos Dietéticos , Proteínas de Soja/metabolismo , Proteínas de Soja/farmacología , Metabolismo de los Lípidos/efectos de los fármacos , MasculinoRESUMEN
SCOPE: Ulcerative colitis (UC) is rapidly increasing worldwide but prolong use of available corticosteroids treatment is associated with numerous adverse effects. There is the urgent need to develop novel therapeutic options. However, this requires the use of suitable disease models, but current models are generated with chemical agents mainly in rodents, which are unable to recapitulate the human occurrence. The aim of this study is to validate the occurrence of spontaneous UC in cynomolgus monkeys and explore the potential of Hericium erinaceus mycelium-derived polysaccharide in reversing UC pathologies. METHODS AND RESULTS: Postmortem bowel evaluation and biochemical analysis including inflammatory markers and fecal occult blood testing (FOBT) as well as nutrition status parameters, confirm the non-artificial induced spontaneous occurrence of UC in cynomolgus monkeys. Subsequently, H. erinaceus mycelium-derived polysaccharide supplementation significantly attenuates UC pathologies, improves nutritional status, reduces the incidence of diarrhea, and reduces inflammation in UC monkeys. Importantly, the polysaccharides administration enhances intestinal function and reshapes the gut microbiota. CONCLUSION: The study confirms the spontaneous UC monkeys can closely mimic the occurrence of UC in humans. Moreover, H. erinaceus mycelium-derived polysaccharide can effectively restore UC in monkeys, which show the prospects as precision nutritional supplement for the management of UC.
Asunto(s)
Basidiomycota , Colitis Ulcerosa , Microbioma Gastrointestinal , Humanos , Animales , Colitis Ulcerosa/tratamiento farmacológico , Macaca fascicularis , Polisacáridos/farmacología , MicelioRESUMEN
The biological effects of ginsenosides are limited by their low oral bioavailability. This study aimed to investigate the effects of particle size reduction and dispersants on the dissolution and bioavailability of ginsenosides in ginseng. Fine ginseng powder (FGP), ultrafine ginseng powder (UGP), and ultrafine ginseng powder with ß-cyclodextrin as the dispersant (UGPD) were prepared using a planetary ball mill from coarse ginseng powder (CGP, as the control). The particle size, morphology, hydration, thermal properties, and in vitro dissolution behavior of ginseng powders were characterized. The relative oral bioavailability of ginsenosides (9 protopanaxadiol (PPD)-type and 7 protopanaxatriol (PPT)-type) was determined in a rat model. Both UGP and UGPD displayed improved physiochemical properties (e.g. reduced particle size, increased hydration and thermal properties). The total in vitro dissolution of ginsenosides from UGPD was â¼17.2% higher than that from CGP; in contrast, UGP did not differ from CGP. More importantly, the in vivo pharmacokinetic study showed that the relative bioavailability of a total of 16 ginsenosides in UGPD was 180.1 ± 9.9% (CGP set as 100%), which was significantly greater than that in FGP and UGP. This suggested that dispersants were essential for preserving the benefits of ultrafine milling by preventing ultra-pulverization induced agglomeration. In particular, PPD-type ginsenosides showed similar deglycosylation trends in in vitro and in vivo experiments; in contrast, the deglycosylation states of PPT-type ginsenosides varied, which might be attributed to the relatively low abundance, glycosylation linkage, and potential involvement of the gut microbiota metabolism. Conclusively, ultrafine milling combined with a dispersant provides a simple and scalable manufacturing process that can effectively improve the bioavailability of ginseng products.